Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 586-591

  Barret, Olivier ^a   Hannestad, Jonas ^b   Vala, Christine ^a   Alagille, David ^a   Tavares, Adriana ^a   Laruelle, Marc ^b   Jennings, Danna ^a   Marek, Ken ^a   Russell, David ^a   Seibyl, John ^a   Tamagnan, Gilles ^a  

^a Molecular NeuroImaging LLC   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

18F MNI 444; A2a receptors; Dosimetry; Kinetic modeling; PET

Indexed keywords

ADENOSINE A2 RECEPTOR; MNI 444 F 18; TRACER; UNCLASSIFIED DRUG; ADENOSINE A2A RECEPTOR; FLUORINE; FUSED HETEROCYCLIC RINGS; MNI-444; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NEUROIMAGING; NORMAL HUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOISOTOPE DISTRIBUTION; REPRODUCIBILITY; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; BRAIN; BRAIN MAPPING; CHEMISTRY; DIAGNOSTIC USE; KINETICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; QUALITY CONTROL; RADIOMETRY; SCINTISCANNING; WHOLE BODY IMAGING; YOUNG ADULT;

ADULT; BRAIN; BRAIN MAPPING; FEMALE; FLUORINE RADIOISOTOPES; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTOR, ADENOSINE A2A; REPRODUCIBILITY OF RESULTS; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84928263545     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.152546     Document Type: Article

References (33)

1. Fuxe K, Agnati LF, Jacobsen K, et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology. 2003;61:S19-S23.
2. Ferré S, Ciruela F, Quiroz C, et al. Adenosine receptor heteromers and their integrative role in striatal function. Scientific World Journal. 2007;7:74-85.
3. Ferré S, Quiroz C, Woods AS, et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des. 2008;14:1468-1474.
4. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002;80:262-270.
5. Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808:1290-1308.
6. Holschbach MH, Bier D, Stusgen S, et al. Synthesis and evaluation of 7-amino-2-(2(3)-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines as potential A2A adenosine receptor antagonists for positron emission tomography (PET). Eur J Med Chem. 2006;41:7-15.
7. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets: what are the challenges? Nat Rev Drug Discov. 2013;12:265-286.
8. 2a receptor. Nature. 1997;388:674-678.
9. El Yacoubi M, Ledent C, Parmentier M, et al. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol. 2001;134:68-77.
10. 18F]-MRS5425. Nucl Med Biol. 2011;38:897-906.
11. 2A receptors in rats. Synapse. 2001;42:164-176.
12. 11C]TMSX. Synapse. 2005;55:133-136.
13. 11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand. J Nucl Med. 2000;41:345-354.
14. 11C]SCH442416. Eur J Nucl Med Mol Imaging. 2005;32:405-413.
15. 11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:679-687.
16. 123I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol. 2013;40:403-409.
17. 123I-MNI-420 in humans. J Nucl Med. 2013;54:1760-1767.
18. 11C] SCH442416 in the rodent brain [abstract]. J Nucl Med. 2013;54 (suppl 2):382.
19. Noguchi J, Ishiwata K, Wakabayashi S, et al. Evaluation of carbon-11-labeled KF17837: a potential CNS adenosine A2a receptor ligand. J Nucl Med. 1998;39:498-503.
20. 11C-methyl]KF 17837 using 3-D-PET: evaluation as a ligand for the study of adenosine A2A receptors. Nucl Med Biol. 1997;24:187-191.
21. Barret O, Hannestad J, Alagille D, et al. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys. J Nucl Med. 2014;55:1712-1718.
22. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224-247.
23. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo :imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
24. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
25. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
26. Sihver W, Schulze A, Wutz W, et al. Autoradiographic comparison of in vitro binding characteristics of various tritiated adenosine A2A receptor ligands in rat, mouse and pig brain and first ex vivo results. Eur J Pharmacol. 2009;616:107-114.
27. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1997;27:322-335.
28. International Commission on Radiological Protection (ICRP). 1990 Recommendations of the International Commission on Radiological Protection. ICRP publication 60. New York, NY: Pergamon Press; 1991.
29. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
30. International Commission on Radiological Protection (ICRP). Limits for Intakes of Radionuclides by Workers. ICRP publication 30 (part 1). Oxford, U.K.: ICRP; 1979.
31. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011;76:1811-1816.
32. 2A receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE. 2011;6:e17338.
33. Deloar HM, Fujiwara T, Shidahara M, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565-574.